Modelled DT Structure
Method: loop building
Template PDB: 6KSW_A
Identity: 100%
Minimized Score: -1395.494 kcal/mol
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0246 | ||||
Gene Name | SLC28A3 | ||||
Protein Name | Concentrative Na(+)-nucleoside cotransporter 3 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: loop building Template PDB: 6KSW_A Identity: 100% Minimized Score: -1395.494 kcal/mol Detail: Structure Info |
||||
Synonyms | CNT 3; CNT3; SLC28A3; Solute carrier family 28 member 3; hCNT3 | ||||
DT Family | Concentrative Nucleoside Transporter (CNT) Family ; | ||||
Tissue Specificity | Expressed in pancreas, bone marrow, trachea,mammary gland, liver, prostate, and regions of intestine, brain,lung, placenta, testis, kidney, and heart. | ||||
Function | This sodium-dependent transporter involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine). Employs a 2:1 sodium/nucleoside ratio. Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazauridine. | ||||
Disease(s) | Acute myeloid leukemia [ICD-11: 2A60] | ||||
Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] | |||||
Endogenous Substrate(s) | Na+; Nucleosides | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(α) Microbiota Influence of This DT |
|||||
(β) Post-translational Modification of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(β) Inter-species Structural Differences |
|||||
(γ) Outward/inward-facing Conformation |
|||||
(δ) Xenobiotics-regulated Structural Variability |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 5 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Clofarabine
|
Approved | Drug Info | Juvenile myelomonocytic leukemia | 2A42 | [1] |
Entecavir
|
Approved | Drug Info | Chronic hepatitis B infection | 1E51.0 | [2] |
Mercaptopurine
|
Approved | Drug Info | Acute lymphoblastic leukemia | 2B33.0 | [3] |
Ribavirin
|
Approved | Drug Info | Hepatitis C virus infection | 1E50.2, 1E51.1 | [4] |
Thioguanine
|
Approved | Drug Info | Acute myeloid leukemia | 2A60 | [3] |
Drug-DT Affinity Assessed by Cell Line |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 2 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Entecavir | Approved | Drug Info | Madin-Darby canine kidney (MDCK) cells-hCNT3 | Km = 23.1 microM | [2] |
Ribavirin | Approved | Drug Info | Xenopus oocytes-hCNT3 and hENT1 | Km = 28.2 microM | [4] |
References | |||||
1 | Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62. | ||||
2 | Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. | ||||
3 | Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15. | ||||
4 | Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.